gated in patients receiving BMT and PBSCT. [5] [6] [7] [8] [9][10][11] A strong inverse correlation between serum granulocyte colony-stimulating factor (G-CSF) level and absolute neuRecently, the ligand for c-mpl has been cloned and initial studies have shown it to be the platelet regulatory trophil count has been demonstrated, 5-9 which suggests that G-CSF plays a critical role in the reconstitution of myeloid factor, thrombopoietin (TPO). To elucidate the role of TPO in the reconstitution of megakaryopoiesis and lineage progenitors after stem cell transplantation. However, of the growth factors studied, including interleukin-3 platelet production after stem cell transplantation, we measured serum TPO levels in nine patients undergoing (IL-3), interleukin-6 (IL-6) and leukemia inhibitory factor (LIF), none have been demonstrated to correlate with plateautologous peripheral blood stem cell transplantation (PBSCT) and in healthy volunteers. Serum TPO levels let recovery after stem cell transplantation. 6,9-11 A possible exception was reported by Testa et al 11 who showed that significantly correlated with the degree of peripheral thrombocytopenia and a strong inverse correlation peak IL-6 levels are directly correlated with the peak of platelet recovery. between serum TPO level and platelet count was observed (r = −0.700, P Ͻ 0.001). Serum TPO levels Recently, the ligand for c-mpl has been cloned; in vitro and in vivo studies have shown that it stimulates both began to rise as the platelet count decreased after chemotherapy. TPO levels peaked at over 25.00 megakaryocytopoiesis and platelet production, suggesting that it is the long-sought platelet regulatory factor, thromfmoles/ml between days 0 and 10; TPO levels then decreased gradually as the platelet count began to rise.
Patients
High-dose chemotherapy followed by peripheral blood Nine patients with various types of malignancies were stem cell transplantation (PBSCT) has become an option evaluated (Table 1 ). There were seven males and two for the treatment of high-risk hematological malignancies females, age range 18 to 67 years. Diagnosis included nonand solid tumors. [1] [2] [3] Following myeloablative chemoHodgkin's lymphoma (NHL) (four), acute myelogenous therapy, the recovery of hematopoiesis is dependent on leukemia (AML) (two), acute lymphoblastic leukemia stem cell self-renewal capacity and differentiation to (ALL) (one), multiple myeloma (MM) (one) and small cell lineage-committed progenitors, which undergo further diflung cancer (SCLC) (one). ferentiation and then maturation to morphologically recognizable precursor cells and terminal cells circulating in perTransplant procedures ipheral blood. 4 Hematopoietic growth factors are thought to play a role in the engraftment of stem cells following
The details of peripheral blood stem cell (PBSC) collection bone marrow transplantation (BMT) or PBSCT. Thus far, and PBSCT procedures have been previously described. (rhG-CSF) (filgrastim) 50 g/m 2 . PBSC were collected during leukocyte recovery using a CS3000 blood cell separmicroplate reader (International Reagents Corporation, Kobe, Japan). The absorbance of each sample was subator (Fenwal, Deerfield, IL, USA), and stored at −130°C.
In the MM patient, CD34
+ cells were separated from total tracted from that of each sample incubated with TN1. The average value of each standard or high TPO serum sample PBSC using an Isolex system (Baxter Healthcare Immunotherapy Division, Round Lake, IL, USA). The pre-transwas subtracted from that of the blank for the standard. The sample concentration was calculated by regression analysis plant conditioning regimen for AML consisted of busulfan (BU) (16 mg/kg) and CY (120 mg/kg); that for NHL confor the standard curve. This ELISA system was highly sensitive and specific for sisted of CY (120 mg/kg), VP-16 (1500 mg/m 2 ) and ranimustin (MCNU) (500 mg/m 2 ); that for MM consisted of human TPO. The lower limit of detection was 0.09 fmoles/ml in serum and no significant cross-reactivity to melphalan (L-PAM) ( istics were determined by Pearson's correlation coefficient. Samples were collected on day −8, and every 2-4 days thereafter until platelet recovery. Serum was separated by centrifugation shortly after collection and was frozen at Results −80°C until assayed.
Control subjects
Measurement of serum level of TPO Serum TPO levels obtained from five healthy volunteers were 0.41 Ϯ 0.23 fmoles/ml (mean Ϯ s.d.). TPO levels in serum were measured by a sandwich enzyme-linked immunosorbent assay (ELISA). 16 Each well in a 96-well flat-bottomed microtiter plate (Maxisorp, PBSCT patients Nunc, Roskilde, Denmark) was coated at 4°C overnight Platelet recovery in the nine patients receiving PBSCT was with 100 l of TN1 (mouse anti-human TPO monoclonal rapid except for the two patients with AML and the median antibody) (Kirin Pharmaceutical Research Laboratory, time to reach 50 × 10 9 /l platelets was 16 days (Table 1) . Gunma, Japan) at a concentration of 10 g/ml in 50 mm
The relationship between the kinetics of serum TPO and carbonate buffer (pH 9.4). After washing twice with 20 mm platelet counts in the blood of seven patients with the fastest Tris-HCl containing 0.5 m NaCl and 0.1% NaN 3 (pH 7.5) platelet recovery is shown in Figure 1 . Serum TPO levels (TBS), 200 l of a blocking reagent (Super Block in TBS; began to rise as the platelet count decreased after highPierce, Rockford, IL, USA) was added to the wells and dose chemotherapy. The TPO level peaked at over 25.00 incubated at room temperature for 30 min. After the blockfmoles/ml between days 0 and 10 and levels then gradually ing reagent was aspirated, 100 l of recombinant human (rh) TPO standard, serum test sample or blank were added to each well and reacted with the coated TN1 at room temperature overnight. After washing with 20 mm Tris-HCl containing 0.5 m NaCl, 0.05% Tween 20 and 0.1% NaN 3 (T-TBS), 100 l of biotinylated anti-rhTPO at a concentration of 500 ng/ml in dilution buffer (T-TBS containing 1% bovine serum albumin and 2% PEG 6000, pH 7.5) was added to each well and incubated at room temperature for 3 h. After washing with T-TBS, 100 l of alkaline phosphatase-conjugated streptavidin (1 mU/ml in dilution buffer; Boehringer Mannheim, Mannheim, Germany) was added to each well, then incubated at room temperature for 1 h. The color was developed using an amplification system (Gibco BRL, Gaithersburg, MD, USA). After washing with T-TBS, 50 l of substrate solution was added to each well, and incubated at room temperature for 40 min. Then 50 l 
Discussion
This study demonstrated a significant correlation between the degree of thrombocytopenia post-transplantation and endogenous TPO production. A strong inverse correlation between serum TPO levels and circulating platelet counts was observed in patients undergoing PBSCT and purified CD34 + PBSCT. These observations suggest that TPO plays a critical role in the reconstitution of megakaryocytopoiesis and platelet production after stem cell transplantation.
To date, various cytokines including IL-3, 18 IL-6, 19 IL-11 20 and LIF 21 have been shown to stimulate the growth of megakaryocytic progenitors. However, in vitro studies have shown that the effects of these cytokines are less potent than those of TPO, and no direct correlation has been observed between the levels of these cytokines and platelet Kuter and Rosenberg 22 have determined the relationship between blood levels of TPO and changes in the circulating platelet mass in rabbits treated with busulfan. As the platelet mass declined, levels of TPO increased inversely and proportionally and peaked during the platelet nadir. Berndecreased as the platelet count began to rise (Figure 1 ). Serum TPO levels significantly correlated with the degree stein et al 23 reported a significant inverse relationship between platelet counts and plasma TPO levels but not of peripheral thrombocytopenia and an inverse correlation was observed between serum levels of TPO and the absolthose of IL-3, IL-11 or LIF during the course of chemotherapy in patients with AML. In addition, Nichol et al 24 ute platelet count (r = −0.70, P Ͻ 0.001) (Figure 2 ). In the patient with myeloma who received purified CD34 + PBSC, demonstrated that the platelet nadir was always associated with the peak of serum TPO which returned towards basethe times required for neutrophil and platelet recovery were similar to those for unfractionated PBSCT; the times to line as platelet counts recovered in patients receiving PBSCT with or without bone marrow. These observations, reach 0.5 × 10 9 /l neutrophils and 50 × 10 9 /l platelets were 12 and 18 days, respectively. In this patient, the serum TPO together with ours, suggest that TPO is a major growth factor for platelets. Two mechanisms have been postulated level reached a significantly elevated level on day 0, and high levels continued until the platelet count began to rise.
concerning the regulation of serum TPO levels. One possible mechanism of TPO clearance from serum is receptorThe kinetics of serum TPO levels were similar in patients receiving unfractionated PBSCT. In the two patients with mediated degradation of TPO by megakaryocytes and platelets. 22, 25, 26 Based on the finding that platelets bear receptors AML, who showed delayed platelet recovery, serum TPO levels rose immediately after PBSCT and high levels confor TPO, Kuter and Rosenberg 22 have proposed that TPO gene expression is constant and that serum levels are continued until the platelet count began to rise. M = male; F = female; SCLC = small cell lung cancer; NHL = non-Hodgkin's lymphoma; AML = acute myelogenous leukemia; MM = multiple myeloma; ALL = acute lymphoblastic leukemia; MNC = mononuclear cells; CFU-GM = colony forming units-granulocyte macrophage; TPO = thrombopoietin; ANC = absolute neutrophil count. a Purified CD34 + PBSCT. 
